BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 25838055)

  • 1. Possible role for interleukins as biomarkers for mortality and recurrence in oral cancer.
    Arduino PG; Menegatti E; Cappello N; Martina E; Gardino N; Tanteri C; Cavallo F; Scully C; Broccoletti R
    Int J Biol Markers; 2015 May; 30(2):e262-6. PubMed ID: 25838055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of interleukins-6 and 8 in saliva as potential biomarkers of oral pre-malignant lesion and oral carcinoma: A breakthrough in salivary diagnostics in Pakistan.
    Khyani IAM; Qureshi MA; Mirza T; Farooq MU
    Pak J Pharm Sci; 2017 May; 30(3):817-823. PubMed ID: 28653927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between salivary interleukin-6 levels and early locoregional recurrence in patients with oral squamous cell carcinoma: preliminary study.
    Sato J; Ohuchi M; Abe K; Satoh T; Abe T; Yamazaki Y; Satoh A; Notani K; Kitagawa Y
    Head Neck; 2013 Jun; 35(6):889-94. PubMed ID: 22887132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-6 predicts recurrence and survival among head and neck cancer patients.
    Duffy SA; Taylor JM; Terrell JE; Islam M; Li Y; Fowler KE; Wolf GT; Teknos TN
    Cancer; 2008 Aug; 113(4):750-7. PubMed ID: 18536030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Relationship between interleukins in the saliva and oral cavity cancer].
    Wang DK; Liao GQ
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2018 Jun; 36(3):325-330. PubMed ID: 29984937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of salivary cytokine levels in oral cancer patients and healthy subjects.
    Katakura A; Kamiyama I; Takano N; Shibahara T; Muramatsu T; Ishihara K; Takagi R; Shouno T
    Bull Tokyo Dent Coll; 2007 Nov; 48(4):199-203. PubMed ID: 18360107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salivary Immunosuppressive Cytokines IL-10 and IL-13 Are Significantly Elevated in Oral Squamous Cell Carcinoma Patients.
    Aziz S; Ahmed SS; Ali A; Khan FA; Zulfiqar G; Iqbal J; Khan AA; Shoaib M
    Cancer Invest; 2015; 33(7):318-28. PubMed ID: 26046681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of Cyfra 21-1 levels in saliva and serum with CK19 mRNA expression in oral squamous cell carcinoma.
    Malhotra R; Urs AB; Chakravarti A; Kumar S; Gupta VK; Mahajan B
    Tumour Biol; 2016 Jul; 37(7):9263-71. PubMed ID: 26779624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in sequential posttreatment salivary IL-6 levels between patients with and patients without locoregional recurrences of oral squamous cell carcinoma: Part III of a cohort study.
    Sato J; Ohuchi M; Wada M; Ohga N; Asaka T; Yoshikawa K; Miyakoshi M; Hata H; Satoh A; Kitagawa Y
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Dec; 120(6):751-60.e2. PubMed ID: 26548727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma.
    St John MA; Li Y; Zhou X; Denny P; Ho CM; Montemagno C; Shi W; Qi F; Wu B; Sinha U; Jordan R; Wolinsky L; Park NH; Liu H; Abemayor E; Wong DT
    Arch Otolaryngol Head Neck Surg; 2004 Aug; 130(8):929-35. PubMed ID: 15313862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Saliva proteome profiling reveals potential salivary biomarkers for detection of oral cavity squamous cell carcinoma.
    Wu CC; Chu HW; Hsu CW; Chang KP; Liu HP
    Proteomics; 2015 Oct; 15(19):3394-404. PubMed ID: 26205615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomics investigation of OSCC-specific salivary biomarkers in a Hungarian population highlights the importance of identification of population-tailored biomarkers.
    Csősz É; Lábiscsák P; Kalló G; Márkus B; Emri M; Szabó A; Tar I; Tőzsér J; Kiss C; Márton I
    PLoS One; 2017; 12(5):e0177282. PubMed ID: 28545132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection.
    Fu YP; Yi Y; Cai XY; Sun J; Ni XC; He HW; Wang JX; Lu ZF; Huang JL; Cao Y; Zhou J; Fan J; Qiu SJ
    Br J Cancer; 2016 Mar; 114(7):767-76. PubMed ID: 27002937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated S100A9 expression in tumor stroma functions as an early recurrence marker for early-stage oral cancer patients through increased tumor cell invasion, angiogenesis, macrophage recruitment and interleukin-6 production.
    Fang WY; Chen YW; Hsiao JR; Liu CS; Kuo YZ; Wang YC; Chang KC; Tsai ST; Chang MZ; Lin SH; Wu LW
    Oncotarget; 2015 Sep; 6(29):28401-24. PubMed ID: 26315114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging.
    Dibble EH; Alvarez AC; Truong MT; Mercier G; Cook EF; Subramaniam RM
    J Nucl Med; 2012 May; 53(5):709-15. PubMed ID: 22492732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salivary and serum level of CYFRA 21-1 in oral precancer and oral squamous cell carcinoma.
    Rajkumar K; Ramya R; Nandhini G; Rajashree P; Ramesh Kumar A; Nirmala Anandan S
    Oral Dis; 2015 Jan; 21(1):90-6. PubMed ID: 24304502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low serum interleukin-6 levels as a predictive marker of recurrence in patients with hepatitis B virus related hepatocellular carcinoma who underwent curative treatment.
    Cho HJ; Kim SS; Ahn SJ; Park SY; Park JH; Kim JK; Wang HJ; Cheong JY; Cho SW
    Cytokine; 2015 Jun; 73(2):245-52. PubMed ID: 25797190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High HMGA2 Expression Correlates with Reduced Recurrence-free Survival and Poor Overall Survival in Oral Squamous Cell Carcinoma.
    Fang CY; Liew PL; Chen CL; Lin YH; Fang CL; Chen WY
    Anticancer Res; 2017 Apr; 37(4):1891-1899. PubMed ID: 28373457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. End Binding 1 (EB1) overexpression in oral lesions and cancer: A biomarker of tumor progression and poor prognosis.
    Kumar M; Mehra S; Thakar A; Shukla NK; Roychoudhary A; Sharma MC; Ralhan R; Chauhan SS
    Clin Chim Acta; 2016 Aug; 459():45-52. PubMed ID: 27208742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcellular differential expression of Ep-ICD in oral dysplasia and cancer is associated with disease progression and prognosis.
    Somasundaram RT; Kaur J; Leong I; MacMillan C; Witterick IJ; Walfish PG; Ralhan R
    BMC Cancer; 2016 Jul; 16():486. PubMed ID: 27421772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.